Detalhe da pesquisa
1.
Modeling viral evolutionary dynamics after telaprevir-based treatment.
PLoS Comput Biol
; 10(8): e1003772, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25101970
2.
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.
J Clin Gastroenterol
; 49(4): 336-44, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24828357
3.
Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies.
J Pharmacokinet Pharmacodyn
; 42(6): 681-98, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26289844
4.
Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study.
J Infect Dis
; 210(12): 1871-80, 2014 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24943725
5.
Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.
Antimicrob Agents Chemother
; 58(9): 5456-65, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24982088
6.
Telaprevir for previously untreated chronic hepatitis C virus infection.
N Engl J Med
; 364(25): 2405-16, 2011 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-21696307
7.
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.
J Virol
; 87(3): 1544-53, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23152524
8.
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.
Clin Infect Dis
; 57(2): 221-9, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23575197
9.
In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.
Antimicrob Agents Chemother
; 57(12): 6236-45, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24100495
10.
Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.
Clin Gastroenterol Hepatol
; 11(2): 193-5, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23159528
11.
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.
Hepatology
; 56(6): 2106-15, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22806681
12.
Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples.
Virol J
; 10: 53, 2013 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23402332
13.
A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.
PLoS Comput Biol
; 8(1): e1002339, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22241977
14.
Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment.
Virol J
; 9: 147, 2012 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-22866919
15.
HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a.
Scand J Gastroenterol
; 46(11): 1362-8, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21815864
16.
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).
J Antimicrob Chemother
; 65(2): 202-12, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19903720
17.
Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.
Antivir Ther
; 23(4): 335-344, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29244026
18.
Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.
Gastroenterology
; 140(3): 755-60, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21255574
19.
Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring.
Clin Infect Dis
; 42(8): 1189-96, 2006 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16575741
20.
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
JAMA
; 293(7): 817-29, 2005 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-15713771